Oncotarget

Research Papers:

Mutational analysis of a Chinese family with oculocutaneous albinism type 2

Xiong Wang, Yaowu Zhu, Na Shen, Jing Peng, Chunyu Wang, Haiyi Liu _ and Yanjun Lu

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:70345-70355. https://doi.org/10.18632/oncotarget.19697

Metrics: PDF 1185 views  |   HTML 2219 views  |   ?  


Abstract

Xiong Wang1, Yaowu Zhu1, Na Shen1, Jing Peng1, Chunyu Wang1, Haiyi Liu2 and Yanjun Lu1

1Department of Laboratory Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China

2Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China

Correspondence to:

Haiyi Liu, email: [email protected]

Yanjun Lu, email: [email protected]

Keywords: OCA2, SLC45A2, mutation, splice site

Received: February 28, 2017     Accepted: June 01, 2017     Published: July 31, 2017

ABSTRACT

Oculocutaneous albinism (OCA) is an autosomal recessive disorder characterized by hypopigmentation of the skin, hair, and eyes accompanied with ophthalmologic abnormalities. Molecular genetic test can confirm the diagnosis of the four subtypes of OCA (OCA1-4). Herein, we report a Chinese family with two patients affected by OCA. Mutations of TYR, OCA2, TYRP1, and SLC45A2 were examined by using PCR-sequencing. Large deletions or duplications of TYR and OCA2 were examined by Multiplex Ligation-dependent Probe Amplification (MLPA) assay. Compound heterozygous mutations of OCA2, (c.808-3C>G and c.2080-2A>G), were identified in both patients characterized with yellow hair and milky skin, heterochromia iridis, and nystagmus. Several computer-assisted approaches predicted that c.808-3C>G and c.2080-2A>G in OCA2 might potentially be pathogenic splicing mutations. No exon rearrangement (deletion/duplication) of TYR and OCA2 was observed in the patients by MLPA analysis. This study suggests that compound heterozygous mutations, (c.808-3C>G and c.2080-2A>G), in OCA2 may be responsible for partial clinical manifestations of OCA.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 19697